Real-World EV Plus Pembro Success Seen in Urothelial Cancer

Published Date: 10 Jul 2026

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Read Full News

Latest News


News All Time

HTTP error: 503 HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503 HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trump slashed US cancer research by 31 percent: Senate report

2.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

FDA approves rivanetin as the first-line treatment for lung cancer.

5.

Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot